RALEIGH, N.C., June 8 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), a medical tissue cohesive products company, today announced
its filing of a 510(K) with the FDA, seeking marketing clearance for its
SOOTHE-N-SEAL(TM) canker sore relief.  The filing is based in part on the
findings of a sponsored 155-patient multi-center clinical study conducted at
Brigham & Women's Hospital, the School of Dentistry at UNC-Chapel Hill, and
the Forsyth Dental Center.
    In the multi-center study, SOOTHE-N-SEAL(TM) canker sore relief was found
to provide immediate and long-lasting pain relief.  In addition,
SOOTHE-N-SEAL(TM) canker sore relief provided a protective barrier that
reduced the pain associated with the irritation of eating and drinking.
    "Based upon primary market research, we believe that there are about 40
million households within the U.S. in which one or more members have suffered
from oral ulcers within the past 6 months," said Mr. Robert V. Toni, President
and CEO of CLOSURE Medical Corporation.  "SOOTHE-N-SEAL(TM) canker sore relief
may provide immediate and long-lasting pain relief from the discomfort
associated with these oral ulcers."
    CLOSURE Medical Corporation is currently seeking a well-positioned OTC
consumer marketing partner for SOOTHE-N-SEAL(TM) canker sore relief.
SOOTHE-N-SEAL(TM) canker sore relief is the first step in developing what
CLOSURE Medical Corporation believes to be a significant platform of OTC
consumer products.
    CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
develops, manufactures and commercializes medical tissue cohesive products
based on its proprietary cyanoacrylate technology.  CLOSURE's nonabsorbable
tissue cohesive products may be used to replace sutures and staples for
certain topical wound closure applications, while its absorbable tissue
cohesive products can potentially be used as tissue cohesives for internal
wound closure and management.  Currently marketed nonabsorbable tissue
cohesive products include DERMABOND* topical skin adhesive, which is used to
replace sutures and staples for closure of certain lacerations and incisions,
OCTYLDENT(R) cohesive, which is used as an adjunct in the treatment of adult
periodontal disease; and NEXABAND(R) topical cohesives, a family of products
used in veterinary wound closure and management.

    * DERMABOND is a trademark of Ethicon, Inc.; SOOTHE-N-SEAL, OCTYLDENT and
      NEXABAND are all trademarks of CLOSURE Medical Corporation.

    This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements.  These factors
include, but are not limited to the early stage of commercialization of the
Company products; the progress of its research and development programs for
future nonabsorbable and absorbable products; the need for regulatory approval
and effects of governmental regulation; technological uncertainties;
dependence on marketing partners, and dependence on patents and trade secrets,
as well as those detailed in the Company's Annual Report on Form 10-K for the
year ended December 31, 1998 filed with the Securities and Exchange
Commission.

Link to this page: